Biovitrum And Syntonix Dose First Hemophilia B Patient In C

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Clinical Trials News
Reply to topic
Biovitrum And Syntonix Dose First Hemophilia B Patient In C
RSS FEED


Joined: 05 Apr 2006
Posts: 19275
Post Posted: Wed May 28, 2008 9:58 pm Reply with quote
Biovitrum AB (STO: BVT) and Syntonix Pharmaceuticals, Inc., a subsidiary of Biogen/Idec (NASDAQ: BIIB) announced the initiation of a phase I/IIa open-label, dose escalation study of a long-acting, recombinant Factor IXFc (FIXFc) protein in patients with hemophilia B. The study is ongoing at clinics in the United States and will assess the safety, tolerability and pharmacokinetics of Factor IXFc in this patient population.

Read more...
View user's profileSend private message
Biovitrum And Syntonix Dose First Hemophilia B Patient In C
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Clinical Trials News
 Reply to topic  
Forum Map
Site Map